Profile data is unavailable for this security.
About the company
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR platform. Anti-TNF platform is focused on fibrosis and anti-tumor necrosis factor (anti-TNF). SCAs platform is focused on drugs which are synthetic cannabidiol (CBD) or cannabigerol (CBG) analogues (SCAs). a7nAChR platform is focused on alpha 7 nicotinic acetylcholine receptor (a7nAChR). It is conducting clinical trials only for certain indications under the anti-TNF platform. The Company is undertaking preclinical research and development activities for the SCA platform.
- Revenue in USD (TTM)0.00
- Net income in USD-12.55m
- Incorporated2016
- Employees4.00
- Location180 Life Sciences Corp3000 El Camino Real, Bldg 4, Ste 200PALO ALTO 94306United StatesUSA
- Phone+1 (650) 507-0669
- Fax+1 (302) 636-5454
- Websitehttps://180lifesciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aclarion Inc | 53.95k | -5.90m | 1.59m | 6.00 | -- | 0.8805 | -- | 29.49 | -4.74 | -4.74 | 0.0146 | 0.20 | 0.0212 | -- | 3.59 | 8,991.67 | -231.70 | -- | -714.18 | -- | -51.53 | -- | -10,937.05 | -- | -- | -111.15 | 0.3212 | -- | 24.75 | -- | 34.38 | -- | -- | -- |
| Axim Biotechnologies Inc | 92.90k | -4.14m | 1.71m | 6.00 | -- | -- | -- | 18.45 | -0.0163 | -0.0163 | 0.0003 | -0.0324 | 0.0233 | -- | -- | 15,483.33 | -103.73 | -154.34 | -- | -390.73 | 16.94 | -- | -4,451.97 | -36,362.71 | -- | -3.14 | -- | -- | 345.05 | -27.38 | -29.10 | -- | -- | -- |
| Pharmagreen Biotech Inc | 4.34k | -524.23k | 1.73m | 0.00 | -- | -- | -- | 397.58 | -0.001 | -0.001 | 0.00001 | -0.0034 | 0.0325 | 0.2118 | 7.55 | -- | -392.99 | -523.11 | -- | -- | 56.22 | -- | -12,079.49 | -307,598.30 | 0.0028 | -1.30 | -- | -- | -- | -- | 35.03 | -- | -- | -- |
| Hi-Great Group Holding Co | 71.99k | -74.35k | 1.78m | -- | -- | -- | -- | 24.73 | -0.0007 | -0.0007 | 0.0007 | -0.0013 | 0.7149 | 0.627 | -- | -- | -73.83 | -- | -- | -- | 51.28 | -- | -103.28 | -- | 0.0099 | -20.74 | -- | -- | -47.32 | -- | -3,789.70 | -- | -- | -- |
| Panbela Therapeutics Inc | 0.00 | -28.56m | 1.79m | 7.00 | -- | -- | -- | -- | -84.64 | -84.64 | 0.00 | -2.18 | 0.00 | -- | -- | 0.00 | -197.23 | -215.89 | -3,522.07 | -476.38 | -- | -- | -- | -- | -- | -143.57 | -- | -- | -- | -- | 27.68 | -- | -- | -- |
| 180 Life Sciences Corp | 0.00 | -12.55m | 1.91m | 4.00 | -- | -- | -- | -- | -28.16 | -28.16 | 0.00 | -0.4439 | 0.00 | -- | -- | 0.00 | -142.80 | -42.39 | -270.23 | -56.41 | -- | -- | -- | -- | -- | -- | 18.20 | -- | -- | -- | 48.52 | -- | -- | -- |
| Cyclacel Pharmaceuticals Inc | 80.00k | -17.61m | 1.95m | 12.00 | -- | 1.79 | -- | 24.43 | -16.14 | -16.14 | 0.0423 | 0.5534 | 0.0065 | -- | 0.0547 | -- | -142.14 | -57.58 | -327.21 | -69.81 | -- | -- | -21,882.50 | -18,789.29 | -- | -100.52 | 0.00 | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
| Novelstem International Corp | 18.00k | -1.65m | 1.97m | 15.00 | -- | -- | -- | 109.39 | -0.0352 | -0.0352 | 0.0004 | -0.0541 | 0.0081 | -- | 8.00 | -- | -63.77 | -- | -- | -- | -- | -- | -7,867.33 | -- | -- | -2.13 | 2.61 | -- | 0.00 | -- | -446.84 | -- | -- | -- |
| VG Life Sciences Inc | 0.00 | -4.30m | 2.11m | 7.00 | -- | -- | -- | -- | -0.0721 | -0.0721 | 0.00 | -0.0491 | 0.00 | -- | -- | -- | -384.41 | -294.08 | -- | -- | -- | -- | -- | -587,591.90 | -- | -1.70 | -- | -- | -- | -- | 16.58 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -9.82m | 2.13m | 8.00 | -- | 0.3384 | -- | -- | -19.42 | -19.42 | 0.00 | 4.79 | 0.00 | -- | -- | 0.00 | -140.74 | -- | -173.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.90 | -- | -- | -- |
| ELEVAI Labs Inc | 2.47m | -4.75m | 2.15m | 18.00 | -- | 0.7615 | -- | 0.8686 | -0.2698 | -0.2698 | 0.1408 | 0.1397 | 0.7249 | 1.04 | 95.33 | 137,407.20 | -139.23 | -- | -285.65 | -- | 69.25 | -- | -192.08 | -- | 0.5439 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
| Kiromic Biopharma Inc | 0.00 | -26.21m | 2.16m | 35.00 | -- | -- | -- | -- | -19.73 | -19.73 | 0.00 | -3.35 | 0.00 | -- | -- | 0.00 | -167.49 | -161.04 | -- | -294.57 | -- | -- | -- | -- | -- | -7.22 | 1.74 | -- | -- | -- | 33.00 | -- | 8.52 | -- |
| Bio Path Holdings Inc | 0.00 | -11.60m | 2.22m | 10.00 | -- | 1.54 | -- | -- | -17.91 | -17.91 | 0.00 | 0.5655 | 0.00 | -- | -- | 0.00 | -199.23 | -70.80 | -321.87 | -76.87 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.94 | -- | -- | -- |
| Zyversa Therapeutics Inc | 0.00 | -21.86m | 2.22m | 7.00 | -- | 0.2092 | -- | -- | -100.63 | -100.63 | 0.00 | 10.32 | 0.00 | -- | -- | 0.00 | -84.85 | -- | -140.95 | -- | -- | -- | -- | -- | -- | -21,828.74 | 0.00 | -- | -- | -- | -340.15 | -- | -- | -- |
Data as of Sep 24 2024. Currency figures normalised to 180 Life Sciences Corp's reporting currency: US Dollar USD
2.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 18.36k | 1.95% |
| Tower Research Capital LLCas of 31 Mar 2024 | 3.44k | 0.37% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 750.00 | 0.08% |
| BlackRock Financial Management, Inc.as of 31 Mar 2024 | 22.00 | 0.00% |
| RBC Dominion Securities, Inc.as of 31 Mar 2024 | 11.00 | 0.00% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 4.00 | 0.00% |
| Semmax Financial Advisors, Inc.as of 31 Mar 2024 | 1.00 | 0.00% |
| IFP Advisors, Inc.as of 30 Jun 2024 | 0.00 | 0.00% |
| HRT Financial LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
